Lymphocyte Homing Antagonists in the Treatment of Inflammatory Bowel Diseases

被引：12
|
作者：
Saruta, Masayuki [1 ]
Papadakis, Konstantinos A. [2 ]
机构：
[1] Jikei Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol,Minato Ku, Tokyo 1050003, Japan
[2] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA
来源：
GASTROENTEROLOGY CLINICS OF NORTH AMERICA | 2014年 / 43卷 / 03期
关键词：
Natalizumab; Vedolizumab; Etrolizumab; Integrins; Chemokine receptors; Inflammatory bowel disease; Ulcerative colitis; Crohn disease; ACTIVE CROHNS-DISEASE; PLACEBO-CONTROLLED TRIAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; HUMANIZED MONOCLONAL-ANTIBODY; CELL-ADHESION MOLECULE-1; THYMUS-EXPRESSED CHEMOKINE; BETA; 7; ULCERATIVE-COLITIS; DOUBLE-BLIND; MAINTENANCE THERAPY;
D O I：
10.1016/j.gtc.2014.05.012
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Lymphocyte homing antagonists represent promising therapeutic agents for the treatment of idiopathic inflammatory bowel disease (IBD). Several critical molecules involved in the recruitment of inflammatory cells in the intestine, including integrins and chemokine receptors, have been successfully targeted for the treatment of IBD. These agents have shown great promise for the induction and maintenance of remission for both Crohn disease and ulcerative colitis. This article discusses currently approved prototypic agents for the treatment of IBD (natalizumab, anti-alpha 4 integrin; vedolizumab, anti-alpha 4 beta 7 integrin), and several other agents in the same class currently under development.
引用
收藏
页码：581 / +
页数：23
相关论文
共 50 条
  • [1] PHYSIOLOGICAL AND MOLECULAR MECHANISMS OF LYMPHOCYTE HOMING IN INFLAMMATORY BOWEL DISEASES
    MATUCHANSKY, C
    [J]. M S-MEDECINE SCIENCES, 1994, 10 (8-9): : 892 - 893
  • [2] Tackling Inflammatory Bowel Diseases: Targeting Proinflammatory Cytokines and Lymphocyte Homing
    Song, Yijie
    Yuan, Man
    Xu, Yu
    Xu, Hongxi
    [J]. PHARMACEUTICALS, 2022, 15 (09)
  • [3] B Lymphocyte intestinal homing in inflammatory bowel disease
    Caterina Defendenti
    Piercarlo Sarzi-Puttini
    Silvia Grosso
    Annamaria Croce
    Olivia Senesi
    Simone Saibeni
    Simona Bollani
    Piero Luigi Almasio
    Savino Bruno
    Fabiola Atzeni
    [J]. BMC Immunology, 12
  • [4] B Lymphocyte intestinal homing in inflammatory bowel disease
    Defendenti, Caterina
    Sarzi-Puttini, Piercarlo
    Grosso, Silvia
    Croce, Annamaria
    Senesi, Olivia
    Saibeni, Simone
    Bollani, Simona
    Almasio, Piero Luigi
    Bruno, Savino
    Atzeni, Fabiola
    [J]. BMC IMMUNOLOGY, 2011, 12
  • [5] LYMPHOCYTE HOMING TO THE GUT IN INFLAMMATORY BOWEL-DISEASE (IBD)
    NAKAMUTA, K
    BLOOM, S
    JEWELL, DP
    [J]. GASTROENTEROLOGY, 1995, 108 (04) : A884 - A884
  • [6] Recent developments on BMPs and their antagonists in inflammatory bowel diseases
    Xie, Zhuo
    Zhou, Gaoshi
    Zhang, Mudan
    Han, Jing
    Wang, Ying
    Li, Xiaoling
    Wu, Qirui
    Li, Manying
    Zhang, Shenghong
    [J]. CELL DEATH DISCOVERY, 2023, 9 (01)
  • [7] Recent developments on BMPs and their antagonists in inflammatory bowel diseases
    Zhuo Xie
    Gaoshi Zhou
    Mudan Zhang
    Jing Han
    Ying Wang
    Xiaoling Li
    Qirui Wu
    Manying Li
    Shenghong Zhang
    [J]. Cell Death Discovery, 9
  • [8] Lymphocyte homing in the pathogenesis of extra-intestinal manifestations of inflammatory bowel disease
    Eksteen, B
    Miles, AE
    Grant, AJ
    Adams, DH
    [J]. CLINICAL MEDICINE, 2004, 4 (02) : 173 - 180
  • [9] Nociceptin antagonists for the treatment of inflammatory bowel disease
    Alt, Carsten
    Shew, Ken
    Tran, Than Thuy
    Polgar, Willma
    Toll, Lawrence
    D'Andrea, Annalisa
    [J]. INFLAMMATION RESEARCH, 2008, 57 : S93 - S93
  • [10] Surgical treatment of inflammatory bowel diseases
    Furst, H
    Schildberg, FW
    [J]. RADIOLOGE, 1998, 38 (01): : 8 - 14
12345